Background: The high disease burden of respiratory syncytial virus RSV infection and renewed focus on developing a vaccine has led to sustained interest in published RSV-related research. We stratified RSV-related publications between by study type, country, research institution and funding body. Conclusions: This review identifies key regions and research institutions which contributed to RSV-related research during as well as the donor agencies which supported this research. Further research investment is required in a number of countries. More research in the elderly and in high-risk adults is required given the lack of studies pertaining to these populations.
6 Things You Should Know About RSV
Respiratory syncytial virus (RSV) - Symptoms and causes - Mayo Clinic
Metrics details. Growing evidence suggests respiratory syncytial virus RSV is an important cause of respiratory disease in adults. However, the adult burden remains largely uncharacterized as most RSV studies focus on children, and population-based studies with laboratory-confirmation of infection are difficult to implement. Indirect modelling methods, long used for influenza, can further our understanding of RSV burden by circumventing some limitations of traditional surveillance studies that rely on direct linkage of individual-level exposure and outcome data. The main outcome considered all ICD-listed respiratory diseases and, for GP episodes, related symptoms. Estimates were adjusted for non-specific seasonal drivers of disease using secular cyclical terms and stratified by age and risk group according to chronic conditions indicating severe influenza risk as per UK recommendations for influenza vaccination. Trial registration NCT
Rsv Research Paper
In healthy adults, RSV, or respiratory syncytial virus, feels like the common cold with a runny nose, chest congestion and cough. However, it is the second leading cause of death in infants. In fact, nearly 40 percent of infants who contract this widespread virus develop severe bronchiolitis or pneumonia, with 1 to 3 percent hospitalized. Each year, there are about 64 million cases and about , deaths due to RSV worldwide. Contracting RSV within the first few months of life can make a child more susceptible to developing asthma later in life.
The results from this study showed that, one month after immunisation, the vaccine had elicited a robust humoral and cellular immunity compared to baseline. According to GSK, these results show that its RSV vaccine candidate can stimulate the immune system in older adults to produce a similar level of antibodies as young adults. RSV remains a significant health threat for older adults over 60 years of age , with approximately , hospitalisations and 24, deaths associated with RSV infections each year in developed countries. GSK is developing a number of candidates within its RSV vaccine portfolio, which also includes maternal and paediatric vaccine candidates.